N-(3-(2-Chlorobenzoyl)-5-ethylthiophen-2-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide, 97%, 250mg

4,6-Dichloro-2-methylnicotinic acid, 95.0%, 5g

4-(2-Bromophenyl)pyridine>98.0%(GC)(T)200mg

Centrifuge filter unit Ultrafree Ultrafree-MC, PVDF membrane, sample volume up to 0.5 ml, 0,10 µm, Non-sterile, 25 Piece(s)

3-chloro-4,5,6,7-tetrahydro-2H-indazole, 98%, 1g

1-(4-Chloro-3-(trifluoromethyl)phenyl)-1H-pyrrole, 97%, 25g

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline-1-carboxylate, 95.0%, 1g

3-Oxoisoindoline-5-carboxylic acid, 95.0%, 10g

3-(Piperidin-4-yl)benzo[d]oxazol-2(3H)-one hydrochloride, 95.0%, 1g

1,1-CYCLOPROPANEDICARBOXAMIDE, N-[4-[[2-[(CYCLOPROPYLCARBONYL)AMINO]-4-PYRIDINYL]OXY]-2,5-DIFLUOROPHENYL]-N'-(4-FLUOROPHENYL)-, 95%, 100mg

Luminol sodium salt hemihydrate, min. 98%, pa, 5 g, glass packaging

Sodium hydroxide solution 10%, extra pure, 10 l, plastic packaging.

(R)-1-(4-Isobutylphenyl)ethan-1-amine, 95+%, 1g